Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

From the articleGLP-1s and schizophrenia: Drug is linked to lower need for acute care in patients with schizophrenia and type 2 diabetes, study suggests